A research group of the Ministry of Health, Labor and Welfare has published for the first time the analysis results of antibodies and side reactions in people who received the Novavax vaccine in the third vaccination of the new coronavirus vaccine.

In addition to confirming the effect of enhancing immunity, it can be said that the rate of adverse reactions such as fever was lower than that of vaccines from other companies.

A research group of the Ministry of Health, Labor and Welfare analyzed the antibody values ​​against the conventional strain before mutation and side reactions of a total of 58 people who received the third vaccination of Novavax vaccine, which began in May this year. has been announced.



Of these, the antibody value was 31.9 times higher on average than before the 3rd inoculation for 7 people one month after the 3rd inoculation.



On the other hand, the percentage of adverse reactions was ▽


10.3% of those who had a fever of 37 degrees 5 minutes or more,


39.7% of general malaise, and


27.6% of headaches.



According to the data on the frequency of adverse reactions to vaccines other than Novavax investigated by the research team,


[People who had a fever of 37 degrees 5 minutes or more]


▽ 39.7% at Pfizer


▽ 62.9% at Moderna



[General malaise]


▽ 69% for Pfizer


▽ 75.6% for Moderna



【Headache】


▽ 55.1% for Pfizer


▽ 64.5%


for Moderna

The result is that it can be said that the frequency is low."

Project Professor Suminobu Ito of the Juntendo University School of Medicine, who is the representative of the research team, said, "Although the number of surveys is still small, an immune-enhancing effect that is expected to prevent aggravation has been confirmed. Vaccine for seasonal influenza. Compared to , the frequency of adverse reactions is statistically about the same or slightly higher, and I would like to collect more numbers and analyze them in detail in the future."

What is Novavax Vaccine?

The new coronavirus vaccine developed by the American pharmaceutical company Novavax is a type of "recombinant protein vaccine".



Using genetic recombination technology, we artificially create and inoculate the "spike protein", which is a marker on the surface of the virus and serves as a marker for antibody attack.



Pfizer and Moderna's "mRNA vaccine" and AstraZeneca's "virus vector vaccine" administer substances and genes that transmit genetic information so that the spike protein of the new coronavirus can be produced in the body to create antibodies. However, the Novavax vaccine induces an immune response by administering the artificial spike protein itself.



In Japan, it is produced at Takeda Pharmaceutical Co., Ltd.'s factory in Yamaguchi Prefecture, and has a contract to supply 150 million doses in one year.



As a public vaccination, vaccination will start at the end of May this year, and it is expected that it will be mainly used for the third vaccination, such as those who have received the AstraZeneca vaccine up to the second time.



Those who can be vaccinated are: ▽For the

1st


and 2nd doses, people over the age of 12


▽For the 3rd dose, people over the age of 18


is asking to be installed.